OBJECTIVES:Cognitive rehabilitation can improve cognition in schizophrenia and prevent disability. It is unknown, however, whether a greater neurobiologic reserve, as measured by cortical volumes, will predict a favorable response to rehabilitation. We investigated this question in early course schizophrenia patients treated withCognitive Enhancement Therapy (CET). METHODS:Outpatients in the early course of schizophrenia or schizoaffective disorder were randomly assigned to CET (n=29) or an Enriched Supportive Therapy control (n=21) and treated for two years. Cortical surface area and gray matter volume data were collected before treatment using structural magnetic resonance imaging. Neurocognition and social cognition were assessed before, and after one and two years of treatment. Moderator analyses examined the impact of pre-treatment cortical surface area and gray matter volume on differential neurocognitive and social-cognitive response to CET. RESULTS: Pre-treatment, whole brain cortical surface area and gray matter volume significantly moderated the effects of CET on social cognition, but not neurocognition. Greater neurobiologic reserve predicted a rapid social-cognitive response to CET in the first year of treatment; patients with less neurobiologic reserve achieved a comparable social-cognitive response by the second year. While nearly every regional measurement significantly contributed to this accelerated social-cognitive treatment response, effects were the strongest in the temporal cortex. CONCLUSIONS: A broad cortical surface area and gray matter reserve is associated with an accelerated social-cognitive response to CET in early schizophrenia, yet the benefits of cognitive rehabilitation are achieved in those with less initial cognitive resources after a longer duration of treatment.
RCT Entities:
OBJECTIVES: Cognitive rehabilitation can improve cognition in schizophrenia and prevent disability. It is unknown, however, whether a greater neurobiologic reserve, as measured by cortical volumes, will predict a favorable response to rehabilitation. We investigated this question in early course schizophreniapatients treated with Cognitive Enhancement Therapy (CET). METHODS: Outpatients in the early course of schizophrenia or schizoaffective disorder were randomly assigned to CET (n=29) or an Enriched Supportive Therapy control (n=21) and treated for two years. Cortical surface area and gray matter volume data were collected before treatment using structural magnetic resonance imaging. Neurocognition and social cognition were assessed before, and after one and two years of treatment. Moderator analyses examined the impact of pre-treatment cortical surface area and gray matter volume on differential neurocognitive and social-cognitive response to CET. RESULTS: Pre-treatment, whole brain cortical surface area and gray matter volume significantly moderated the effects of CET on social cognition, but not neurocognition. Greater neurobiologic reserve predicted a rapid social-cognitive response to CET in the first year of treatment; patients with less neurobiologic reserve achieved a comparable social-cognitive response by the second year. While nearly every regional measurement significantly contributed to this accelerated social-cognitive treatment response, effects were the strongest in the temporal cortex. CONCLUSIONS: A broad cortical surface area and gray matter reserve is associated with an accelerated social-cognitive response to CET in early schizophrenia, yet the benefits of cognitive rehabilitation are achieved in those with less initial cognitive resources after a longer duration of treatment.
Authors: Richard D Sanders; Daniel N Allen; Steven D Forman; Thaddeus Tarpey; Matcheri S Keshavan; Gerald Goldstein Journal: Psychiatry Res Date: 2005-01-30 Impact factor: 3.222
Authors: Rahul S Desikan; Florent Ségonne; Bruce Fischl; Brian T Quinn; Bradford C Dickerson; Deborah Blacker; Randy L Buckner; Anders M Dale; R Paul Maguire; Bradley T Hyman; Marilyn S Albert; Ronald J Killiany Journal: Neuroimage Date: 2006-03-10 Impact factor: 6.556
Authors: Christos Davatzikos; Dinggang Shen; Ruben C Gur; Xiaoying Wu; Dengfeng Liu; Yong Fan; Paul Hughett; Bruce I Turetsky; Raquel E Gur Journal: Arch Gen Psychiatry Date: 2005-11
Authors: J M Goldstein; J M Goodman; L J Seidman; D N Kennedy; N Makris; H Lee; J Tourville; V S Caviness; S V Faraone; M T Tsuang Journal: Arch Gen Psychiatry Date: 1999-06
Authors: Monte S Buchsbaum; Lina Shihabuddin; Erin A Hazlett; Johannes Schröder; Mehmet M Haznedar; Peter Powchik; Jacqueline Spiegel-Cohen; Tsechung Wei; Melissa B Singer; Kenneth L Davis Journal: Schizophr Res Date: 2002-05-01 Impact factor: 4.939
Authors: Toshikazu Ikuta; Philip R Szeszko; Patricia Gruner; Pamela DeRosse; Juan Gallego; Anil K Malhotra Journal: Schizophr Res Date: 2012-03-09 Impact factor: 4.939
Authors: Nikolaos Koutsouleris; Lana Kambeitz-Ilankovic; Stephan Ruhrmann; Marlene Rosen; Anne Ruef; Dominic B Dwyer; Marco Paolini; Katharine Chisholm; Joseph Kambeitz; Theresa Haidl; André Schmidt; John Gillam; Frauke Schultze-Lutter; Peter Falkai; Maximilian Reiser; Anita Riecher-Rössler; Rachel Upthegrove; Jarmo Hietala; Raimo K R Salokangas; Christos Pantelis; Eva Meisenzahl; Stephen J Wood; Dirk Beque; Paolo Brambilla; Stefan Borgwardt Journal: JAMA Psychiatry Date: 2018-11-01 Impact factor: 21.596
Authors: Veronica B Perez; Melissa Tarasenko; Makoto Miyakoshi; Sean T Pianka; Scott D Makeig; David L Braff; Neal R Swerdlow; Gregory A Light Journal: Neuropsychopharmacology Date: 2017-01-31 Impact factor: 7.853
Authors: Kamilla W. Miskowiak; Julie L. Forman; Maj Vinberg; Hartwig R. Siebner; Lars V. Kessing; Julian Macoveanu Journal: J Psychiatry Neurosci Date: 2020-05-01 Impact factor: 6.186
Authors: Yvonne B Suijkerbuijk; Frederieke G Schaafsma; Joost C van Mechelen; Anneli Ojajärvi; Marc Corbière; Johannes R Anema Journal: Cochrane Database Syst Rev Date: 2017-09-12